Circulation reports · 2026
Safety and Efficacy of Ponatinib for Pulmonary Tumor Thrombotic Microangiopathy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sato Kimi, Kawamatsu Naoto, Yamamoto Masayoshi, Machino-Ohtsuka Tomoko, Sakamoto Tatsuhiro, Yamada Takeshi, Yamamoto Yoshiyuki, Homma Masato, Mathis Bryan J, Sekine Ikuo, Ishizu Tomoko
Аннотация
BACKGROUND: We evaluated the safety and efficacy of ponatinib, a multi-target tyrosine kinase inhibitor, for pulmonary tumor thrombotic microangiopathy (PTTM).
METHODS AND RESULTS: We conducted a single-center, open-label, single-arm, prospective study; 3 patients associated with ovarian, breast, and gastric carcinomas were enrolled and received oral ponatinib for 2 weeks. All died from PTTM progression with no severe ponatinib-related adverse events.
CONCLUSIONS: This study failed to demonstrate ponatinib efficacy. Further studies may evaluate the effect of different biochemical targets on PTTM.
METHODS AND RESULTS: We conducted a single-center, open-label, single-arm, prospective study; 3 patients associated with ovarian, breast, and gastric carcinomas were enrolled and received oral ponatinib for 2 weeks. All died from PTTM progression with no severe ponatinib-related adverse events.
CONCLUSIONS: This study failed to demonstrate ponatinib efficacy. Further studies may evaluate the effect of different biochemical targets on PTTM.